Silmitasertib - Senhwa Biosciences

Drug Profile

Silmitasertib - Senhwa Biosciences

Alternative Names: CX-4945

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer Cylene Pharmaceuticals; Senhwa Biosciences; Stanford University School of Medicine
  • Class 3-ring heterocyclic compounds; Antineoplastics; Carboxylic acids; Naphthyridines; Small molecules
  • Mechanism of Action Casein kinase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cholangiocarcinoma
  • Phase I Giant lymph node hyperplasia; Multiple myeloma; Solid tumours
  • Preclinical Medulloblastoma

Most Recent Events

  • 01 Nov 2018 US FDA approves IND application for silmitasertib in Basal cell carcinoma
  • 12 Sep 2018 Phase I development is ongoing in USA (Senhwa Biosciences pipeline, September 2018)
  • 12 Jun 2018 Senhwa Biosciences and Pediatric Brain Tumor Consortium enter into a clinical trial agreement for the conduction of a phase I/II trial in Medulloblastoma (Recurrent, In adults, In children, In adolescents) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top